Tag Archives: EC

Europe: More Direct-Acting Antivirals, More Controversy

The storms raging across Europe—and beyond—over the pricing of new hepatitis C treatments have been intensified by the European Union’s approval last week of the latest directly-acting antiviral, Bristol-Myers Squibb’s Daklinza (daclatasvir). Just two months after the European Medicines Agency gave a positive opinion on the drug, the formal authorization was delivered for use in […]
Posted in Europe, Global, Guest Blog, Op-Ed, pricing, Regulatory | Also tagged , , , , , | Leave a comment

The European Parliament’s New Term: What Can We Expect?

As Europe departs for its annual holiday—sacrosanct, even amid the continuing economic woes, the multiple crises in the Middle East, and the dark mysteries of Russia’s intentions in its former satellites—the question remains unresolved as to what to expect from the new European Parliament in the new term. Philip Ward considers the options in this […]
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , | Leave a comment

Europe's Mooted 'Passport for Physicians': Implications for Patients

Europe moved one step closer to a passport for physicians in early October. The European Parliament gave its backing to creating a virtual professional qualifications card that will allow doctors, pharmacists, and other professionals to practice in another EU country. The system also envisages an alert system, so that health professionals barred in one country […]
Posted in Europe, Global, Guest Blog, Strategy | Also tagged , , , , | Leave a comment

European Pharma Gears Up for Horizon 2020

European Pharma Gears Up for Horizon 2020 The ink is not yet dry on the European Union’s Horizon 2020 agreement to invest some €70 billion ($92 bn) in research over the next seven years, and already contenders for funding are jostling for attention. Europe’s biggest drug industry association EFPIA scored something of a coup by […]
Posted in Europe, Global, Guest Blog, Op-Ed | Also tagged , , , , , | Leave a comment

EU Tense as Crunch-Time for Counterfeits Approaches

By Reflector, Pharm Exec’s Brussels correspondent. Tensions are rising in Europe’s pharmaceutical sector as crunch-time approaches for the legislation to combat counterfeits. By this time next year, the European Commission is due to have decided on the mechanisms required to put into effect the European Union’s hugely complex new rules to keep falsified medicines out […]
Posted in Europe, Global, Guest Blog | Also tagged , , , , , | Leave a comment
  • Categories

  • Meta